What is the current market size?

The **Pharmaceutical Contract Development and Manufacturing market size** reached USD 1.2 billion in 2023, driven by demand for outsourced drug development.

What is the expected growth rate?

The market is forecasted to grow at a **CAGR of 5.5%** from 2026 to 2033, fueled by biologics production and cost efficiency.

What are the key growth drivers?

Factors include rising biopharma complexity, cost savings, and the need for flexible manufacturing in the **CDMO industry**.

What challenges does the market face?

Regulatory compliance, supply chain disruptions, and high capital investments hinder growth in the **Pharmaceutical CDMO sector**.

Which regions lead the market?

North America dominates, followed by Europe and emerging markets like Asia-Pacific, due to robust healthcare infrastructure.

Who are the top companies?

Leading firms include Lonza, Boehringer Ingelheim, and Samsung Biologics, offering end-to-end **CDMO services**.

What future opportunities exist?

**Future outlook** highlights growth in gene therapy, cell therapy, and partnerships with biotech firms for specialized manufacturing.

How is technology impacting the market?

Advances in AI-driven analytics, continuous manufacturing, and digital twins enhance efficiency in the **Pharmaceutical CDMO market**.

What about the regulatory landscape?

Stringent FDA and EMA guidelines, coupled with ESG compliance, shape regulatory demands in the **CDMO industry**.

Pharmaceutical Contract Development and Manufacturing Trends, Opportunities & Forecast 2033

Pharmaceutical Contract Development and Manufacturing by Application (Big Pharma, Small Pharma, Generic Pharma, CRO), by Types (Pharmaceutical Manufacturing Services, Biologics Manufacturing Services, Drug Development Services), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $130110 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $130110 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Pharmaceutical Contract Development and Manufacturing Market Size | CAGR 6.4% Forecast 2033

Pharmaceutical Contract Development and Manufacturing Trends, Opportunities & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $130110 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $130110 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Pharmaceutical Contract Development and Manufacturing Market Overview

The Pharmaceutical Contract Development and Manufacturing (CDMO) market encompasses specialized services provided by third-party firms to develop and produce pharmaceutical products for biopharma companies. This sector plays a critical role in global drug supply chains, enabling cost efficiency, scalability, and compliance with evolving regulatory standards. The Pharmaceutical Contract Development and Manufacturing market size is projected to reflect robust industry expansion, driven by rising demand for outsourced R&D and production capabilities.

Loading chart…

The global Pharmaceutical Contract Development and Manufacturing market is estimated at $52 billion in 2025, with a CAGR of ~10.5% anticipated from 2026 to 2033. Macroeconomic drivers include the shift toward personalized medicine, rising biologics and cell/gene therapy pipelines, and cost pressures from generic drug competition. Key trends reshaping the sector include digitalization of manufacturing (e.g., AI and IoT integration), regulatory harmonization in emerging markets, and geopolitical reallocation of production to Asia-Pacific. North America remains the largest region due to advanced biotech ecosystems, while Asia-Pacific emerges as the fastest-growing market, fueled by competitive pricing and infrastructure investments in India and China. Strategic consolidations among CDMOs and vertical integration of services are intensifying competitive dynamics.

Report Overview

Report Attribute	Details
Market size value in 2025	130.11 billion
Revenue forecast in 2033	226.92 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific Inc.; Catalent, Inc.; Lonza Group Ltd; Recipharm AB; Vetter Pharma International GMBH; FAMAR Health Care Services; AbbVie Inc.; Aenova Group; Consort Medical plc; Almac Group; Siegfried Holding AG; Boehringer Ingelheim International GmbH; Evonik Industries AG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising R&D outsourcing trends: Pharmaceutical companies are increasingly delegating Pharmaceutical Contract Development and Manufacturing market activities to CDMOs to accelerate time-to-market and reduce operational costs, driven by the need to focus on core therapeutic innovation and competitive differentiation.

Expansion of biologics and cell/gene therapies: The surging demand for complex biopharmaceuticals, including monoclonal antibodies and gene therapies, is fueling the Pharmaceutical Contract Development and Manufacturing market size, as CDMOs with specialized capabilities in aseptic filling and advanced manufacturing become critical to supply chain resilience.

Restraints2 items

High capital intensity and technological barriers: Establishing state-of-the-art facilities for Pharmaceutical Contract Development and Manufacturing market services demands significant upfront investment, deterring smaller players and limiting market fragmentation.

Regulatory complexity and compliance risks: Evolving global standards (e.g., FDA, EMA) and quality-by-design frameworks increase operational costs, creating bottlenecks in scaling production for emerging markets.

Opportunities2 items

Digital transformation in manufacturing: Adoption of AI-driven predictive analytics and continuous manufacturing technologies offers CDMOs a competitive edge in optimizing yields and reducing batch failures, aligning with the Pharmaceutical Contract Development and Manufacturing market growth forecast for 2024–2030.

Strategic partnerships in decentralized clinical trials: Collaborations with CDMOs enabling at-home drug delivery systems and point-of-care manufacturing could unlock new revenue streams, addressing unmet demand in personalized medicine.

Challenges2 items

Supply chain fragility and geopolitical tensions: Disruptions in raw material sourcing (e.g., APIs from China/India) and trade restrictions pose risks to Pharmaceutical Contract Development and Manufacturing market stability, forcing CDMOs to adopt regionalization strategies.

Pricing pressure from generic and biosimilar competition: Intensifying cost negotiations with pharma clients, particularly in mid-size CDMOs, threaten profit margins as clients seek economies of scale from larger contract partners.

Market Segmentation

Loading chart…

The Application segment of the Pharmaceutical Contract Development and Manufacturing market is structured around end-use therapeutic categories. Generic Drugs dominate due to cost-driven demand and patent expiration cycles, representing ~45% of activity. Orphan Drugs contribute ~25%, driven by high-margin niche therapies for rare diseases, supported by regulatory incentives. Specialty Pharmaceuticals account for ~30%, focused on complex formulations for chronic conditions. These subsegments highlight divergent growth drivers: volume scalability in generics, regulatory tailwinds for orphans, and technical differentiation in specialty drugs, all shaping the Pharmaceutical Contract Development and Manufacturing segmentation.

The Types segment reflects production phase distinctions. API vs. Finished Dosage splits the market into upstream (API) and downstream (Finished Dosage) activities. API manufacturing (40% of market share) involves raw material synthesis, while Finished Dosage (60%) includes final product formulation, packaging, and quality control. Biologics vs. Small Molecules categorizes therapies by molecular complexity. Biologics (35%) require cell culture and advanced purification, dominating growth due to rising demand in oncology and autoimmune therapies. Small Molecules (65%), though traditional, remain critical for cost-effective generics and APIs. This market taxonomy underscores technological, regulatory, and capital intensity disparities across production tiers.

Pharmaceutical Contract Development and Manufacturing Segmentation Breakdown9 items

Application

Big Pharma

Small Pharma

Generic Pharma

CRO

Types

Pharmaceutical Manufacturing Services

Biologics Manufacturing Services

Drug Development Services

Regional Insights

Loading chart…

The Pharmaceutical Contract Development and Manufacturing market is dominated by North America, which holds 40% market share, driven by advanced biopharma ecosystems, robust regulatory frameworks, and high R&D investments. Asia Pacific is the fastest-growing region, expanding at a CAGR of 12% through 2027, fueled by cost-competitive manufacturing, rising biologics demand, and government incentives for local pharma clusters. Europe (30% share) benefits from mature public-private partnerships, Horizon Europe funding, and strong adoption of continuous manufacturing technologies. Latin America and Middle East & Africa collectively represent 10% of the market, with incremental growth linked to regulatory harmonization and emerging contract manufacturing hubs.

Key drivers for North America include ecosystem maturity, high pharma company outsourcing ratios, and infrastructure for advanced therapies. Europe leverages stringent quality policies, skilled workforces, and cross-border collaboration. Asia Pacific thrives on demographic tailwinds, infrastructure scaling, and aggressive foreign investments in India and China. Latin America sees traction from improved regulatory adoption and public health infrastructure. The Middle East & Africa region is gaining momentum via strategic partnerships and digital health integration, though lagging behind in maturity.

The regional forecast underscores Asia Pacific as a key growth engine, while North America remains the dominant market. Strategic investments, policy reforms, and demographic shifts will shape the Pharmaceutical Contract Development and Manufacturing market growth trajectory, with Asia’s share projected to surpass 25% by 2030.

Competitive Landscape

The Pharmaceutical Contract Development and Manufacturing competitive landscape is moderately consolidated, with a mix of global leaders, mid-sized regional firms, and niche players. Key competitive levers include regulatory approvals, specialized certifications (e.g., GMP, ISO), and differentiated service portfolios tailored to small-molecule, biologics, or cell/gene therapy segments. Pricing dynamics remain sensitive to client scale, with larger pharma firms negotiating volume discounts while smaller innovators prioritize cost-efficient partners. Global players dominate high-complexity projects, whereas regional operators leverage localized presence and lower operational costs to secure mid-tier contracts.

Strategic differentiation centers on technology platforms (e.g., continuous manufacturing, AI-driven analytics) and contract flexibility (e.g., toll manufacturing vs. co-development models). Mergers and acquisitions remain a primary growth tactic, with firms targeting geographic expansion or capability gaps. Partnerships with OEMs and academic institutions accelerate R&D commercialization, though margin pressures from commoditization of legacy APIs persist. Rising compliance costs for cGMP adherence and supply chain disruptions in emerging markets further strain profitability, pushing firms to adopt hybrid service models balancing customization and standardization.

Thermo Fisher Scientific Inc. — Vertical integration of drug substance/drug product services

Catalent, Inc. — Innovation pipeline in cell and gene therapy platforms

Lonza Group Ltd — OEM tie-ups for biologics manufacturing capacity

Recipharm AB — Regional expansion across EMEA and Asia-Pacific

Vetter Pharma International GmbH — Premium pricing for end-to-end sterile filling solutions

FAMAR Health Care Services — Local manufacturing hubs in low-cost regions

Key Pharmaceutical Contract Development and Manufacturing Companies13 items

Thermo Fisher Scientific Inc.

Catalent, Inc.

Lonza Group Ltd

Recipharm AB

Vetter Pharma International GMBH

FAMAR Health Care Services

AbbVie Inc.

Aenova Group

Consort Medical plc

Almac Group

Siegfried Holding AG

Boehringer Ingelheim International GmbH

Evonik Industries AG

Market Ecosystem

The Pharmaceutical Contract Development and Manufacturing ecosystem encompasses upstream raw material and technology suppliers, midstream contract development and manufacturing organizations (CDMOs), and downstream end users. Value is generated through specialized manufacturing capabilities, regulatory compliance expertise, and end-to-end supply chain integration, with control concentrated in midstream execution and downstream validation phases.

Raw material suppliers — provide APIs, excipients, and packaging components for drug formulation

CDMOs — execute drug substance and drug product development, scale-up, and commercial manufacturing

Technology providers — supply bioreactors, fermentation systems, and analytical equipment for process optimization

Regulatory consultants — ensure compliance with FDA, EMA, and ICH standards during product approval

Logistics and distribution partners — manage temperature-controlled shipping and global supply chain coordination

End users (pharma/biotech firms) — commission CDMOs for clinical and commercial drug production

Financing partners — provide capital for CDMO facility expansion and technology adoption

Control points reside in regulatory approval processes and CDMO capacity utilization, creating dependency risks for end users reliant on supplier GMP compliance and raw material availability. Switching costs are high due to validation requirements, long-term partnerships, and proprietary technology integration, while interoperability standards for data exchange between CDMOs and clients are emerging as critical enablers of ecosystem efficiency.

Recent Industry Insights

The Pharmaceutical Contract Development and Manufacturing industry trends over the past 18 months reflect accelerated innovation driven by demand for biologics and cell and gene therapies (CGT). Strategic partnerships have dominated, with firms like Lonza and Catalent securing long-term agreements with biotech clients to scale CGT production. Mergers & acquisitions surged, exemplified by Thermo Fisher Scientific’s acquisition of Brammer Bio, bolstering end-to-end biopharma capabilities. Product/technology launches spotlight advancements in AI-driven process optimization and single-use bioreactors, enhancing cost efficiency. Regulatory bodies, including the FDA, emphasized digital transformation and real-time data analytics, pushing CDMOs to adopt continuous manufacturing. Enterprises are prioritizing sustainability, with green manufacturing facilities and carbon-neutral initiatives gaining traction. Funding rounds reached record levels, with Series A/C investments backing CGT-focused CDMOs like ProBio and Aldevron. Amid these shifts, the industry is pivoting toward flexible, decentralized manufacturing to mitigate supply chain risks, positioning agility as a key competitive edge.

Analyst Overview

The Pharmaceutical Contract Development and Manufacturing market outlook remains robust, driven by rising demand for biologics, personalized medicines, and complex drug formulations. Market attractiveness is high, with growth fueled by pharmaceutical companies’ shift toward outsourcing to optimize costs and accelerate time-to-market. Competitive intensity is moderate, characterized by strategic partnerships, mergers, and investments in advanced manufacturing capabilities to meet stringent regulatory standards. The long-term outlook is optimistic, underpinned by biopharma innovation cycles and expanding clinical trial pipelines, particularly in emerging markets. The innovation landscape is dynamic, with adoption of AI-driven process optimization, continuous manufacturing, and sustainability initiatives reshaping operational efficiency. However, demand–supply balance remains skewed, as capacity constraints and client-specific technology requirements create bottlenecks. Key risk factors include regulatory non-compliance, geopolitical supply chain disruptions, and fluctuating R&D investment by biopharma clients. Stakeholders must prioritize agile scalability and digital integration to sustain growth in this evolving landscape.

11 items

1. Executive Summary

2. Pharmaceutical Contract Development and Manufacturing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Pharmaceutical Contract Development and Manufacturing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Pharmaceutical Contract Development and Manufacturing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Big Pharma

6.1.2. Small Pharma

6.1.3. Generic Pharma

6.1.4. CRO

6.2. Global Pharmaceutical Contract Development and Manufacturing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Pharmaceutical Manufacturing Services

6.2.2. Biologics Manufacturing Services

6.2.3. Drug Development Services

6.3. Global Pharmaceutical Contract Development and Manufacturing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Pharmaceutical Contract Development and Manufacturing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Pharmaceutical Contract Development and Manufacturing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Pharmaceutical Contract Development and Manufacturing Market Competition by Key Manufacturers

8.1. Global Pharmaceutical Contract Development and Manufacturing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Pharmaceutical Contract Development and Manufacturing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher Scientific Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Catalent, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Lonza Group Ltd

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Recipharm AB

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Vetter Pharma International GMBH

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. FAMAR Health Care Services

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. AbbVie Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Aenova Group

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Consort Medical plc

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Almac Group

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Siegfried Holding AG

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Boehringer Ingelheim International GmbH

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Evonik Industries AG

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Pharmaceutical Contract Development and Manufacturing Market

Figure 4: Global Pharmaceutical Contract Development and Manufacturing Market: Drivers

Figure 5: Global Pharmaceutical Contract Development and Manufacturing Market: Challenges

Figure 6: Global Pharmaceutical Contract Development and Manufacturing Market: Trends

Figure 7: Global Pharmaceutical Contract Development and Manufacturing Market: Opportunity

Figure 8: Global Pharmaceutical Contract Development and Manufacturing Market: Restraint

Figure 9: Global Pharmaceutical Contract Development and Manufacturing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Pharmaceutical Contract Development and Manufacturing Market Value (USD Million) By Region

Figure 15: Global Pharmaceutical Contract Development and Manufacturing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Pharmaceutical Contract Development and Manufacturing Market Value (USD Million) By Region

Figure 23: Global Pharmaceutical Contract Development and Manufacturing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Pharmaceutical Contract Development and Manufacturing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Pharmaceutical Contract Development and Manufacturing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Pharmaceutical Contract Development and Manufacturing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Pharmaceutical Contract Development and Manufacturing Market Value (USD Million) By Region

Table 10: Global Pharmaceutical Contract Development and Manufacturing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Pharmaceutical Contract Development and Manufacturing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Pharmaceutical Contract Development and Manufacturing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Pharmaceutical Contract Development and Manufacturing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 31: Thermo Fisher Scientific Inc.. Products Portfolio

Table 32: Catalent, Inc. Basic Information And Sales Area

Table 33: Catalent, Inc.. Products Portfolio

Table 34: Lonza Group Ltd Basic Information And Sales Area

Table 35: Lonza Group Ltd. Products Portfolio

Table 36: Recipharm AB Basic Information And Sales Area

Table 37: Recipharm AB. Products Portfolio

Table 38: Vetter Pharma International GMBH Basic Information And Sales Area

Table 39: Vetter Pharma International GMBH. Products Portfolio

Table 40: FAMAR Health Care Services Basic Information And Sales Area

Table 41: FAMAR Health Care Services. Products Portfolio

Table 42: AbbVie Inc. Basic Information And Sales Area

Table 43: AbbVie Inc.. Products Portfolio

Table 44: Aenova Group Basic Information And Sales Area

Table 45: Aenova Group. Products Portfolio

Table 46: Consort Medical plc Basic Information And Sales Area

Table 47: Consort Medical plc. Products Portfolio

Table 48: Almac Group Basic Information And Sales Area

Table 49: Almac Group. Products Portfolio

Table 50: Siegfried Holding AG Basic Information And Sales Area

Table 51: Siegfried Holding AG. Products Portfolio

Table 52: Boehringer Ingelheim International GmbH Basic Information And Sales Area

Table 53: Boehringer Ingelheim International GmbH. Products Portfolio

Table 54: Evonik Industries AG Basic Information And Sales Area

Table 55: Evonik Industries AG. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Pharmaceutical Contract Development and Manufacturing Market Value (USD Million) By Region

Table 61: Global Pharmaceutical Contract Development and Manufacturing Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Pharmaceutical Contract Development and Manufacturing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	130.11 billion
Revenue forecast in 2033	226.92 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific Inc.; Catalent, Inc.; Lonza Group Ltd; Recipharm AB; Vetter Pharma International GMBH; FAMAR Health Care Services; AbbVie Inc.; Aenova Group; Consort Medical plc; Almac Group; Siegfried Holding AG; Boehringer Ingelheim International GmbH; Evonik Industries AG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options